JonesTrading Maintains Buy on Crinetics Pharmaceuticals, Raises Price Target to $56
JonesTrading Maintains Buy on Crinetics Pharmaceuticals, Raises Price Target to $56
JoneStrading維持對Crinetics Pharmicals的買入，將目標股價上調至56美元
JonesTrading analyst Lina Kaminski maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and raises the price target from $52 to $56.
瓊斯交易分析師麗娜·卡明斯基維持Crinetics Pharmicals（納斯達克股票代碼：CRNX）的買入並將目標股價從52美元上調至56美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。